Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
C Peschel, JT Hartmann, A Schmittel, C Bokemeyer… - Lung cancer, 2008 - Elsevier
OBJECTIVE: To evaluate the progression-free rate (PFR) at 3 months (13±1 weeks),
antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin …
antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin …
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
C Peschel, JT Hartmann, A Schmittel… - Lung cancer …, 2008 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks), antitumor
response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as …
response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as …
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
C Peschel, JT Hartmann, A Schmittel, C Bokemeyer… - 2008 - mediatum.ub.tum.de
OBJECTIVE: To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks),
antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin …
antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin …
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
C Peschel, JT Hartmann, A Schmittel… - Lung Cancer …, 2007 - europepmc.org
Objective To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks), antitumor
response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as …
response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as …
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
C Peschel, JT Hartmann, A Schmittel, C Bokemeyer… - Lung Cancer, 2008 - infona.pl
To evaluate the progression-free rate (PFR) at 3 months (13±1 weeks), antitumor response,
time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h …
time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h …
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
C Peschel, JT Hartmann, A Schmittel… - Lung …, 2008 - lungcancerjournal.info
Objective To evaluate the progression-free rate (PFR) at 3 months (13±1 weeks), antitumor
response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as …
response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as …
[引用][C] Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
C PESCHEL, JT HARTMANN, A SCHMITTEL… - Lung …, 2008 - pascal-francis.inist.fr
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small
cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
C Peschel, JT Hartmann, A Schmittel, C Bokemeyer… - Lung Cancer, 2008 - infona.pl
To evaluate the progression-free rate (PFR) at 3 months (13±1 weeks), antitumor response,
time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h …
time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h …